Presentation is loading. Please wait.

Presentation is loading. Please wait.

CDER Meeting: Surrogate Markers of Immunity Presenter: Judith A. Britz, Ph.D. October 16, 2000.

Similar presentations


Presentation on theme: "CDER Meeting: Surrogate Markers of Immunity Presenter: Judith A. Britz, Ph.D. October 16, 2000."— Presentation transcript:

1 CDER Meeting: Surrogate Markers of Immunity Presenter: Judith A. Britz, Ph.D. October 16, 2000

2

3 HIV Pathogenesis Cellular Immune Function Tests have Prognostic Value: –independent of CD4+ Count –Up to 1 year before CD4 Count Decline Progressive Loss of Function as measured by response to: –Mitogens –Alloantigens –Recall Antigens Clerici et al. 1989. J. Clin. Invest. 84: 1892 Dolan et al. 1995. J. Infect. Dis.172:79

4 Immune Reconstitution LPA Reactivity to HIV p24 rAg enhanced: –Long Term Non-Progressors –Following early treatment of acute HIV infection –Strengthened by treatment interruption (in some patients) Rosenberg, E.S et al. 1997. Science 278: 1447 Rosenberg, E.S. et al. 2000. Nature 408: 523

5 Lymphoproliferation (LPA) Traditional method for evaluating cell-mediated immune function: Time-consuming: 5-7 Days Radioactive Labor-intensive Not widely available Not standardized Shipping impact Not practical for clinical use Betensky et al. 2000. Clin. Diag. Lab. Immunol. 7(5): 759

6 Objectives Clinical Correlate of Cell-Mediated Immunity 24 Hours or less Non-Radioactive Whole Blood or PBMCs Cost Effective Adaptable to Test with Multiple Antigens Standardized

7 ATP ATP ATP Cell lysis to release ATP ATP detection reagents Luminometer Measure light intensity Lymphocyte Stimulation Wash Incubate Magnetic separation of CD4 cells. 4 hours to overnight

8 DPM x 100 LPA assay 96 HRS ATP ng/mL In vitro CMI Overnight Comparison with LPA

9 Reference Sottong, P.R., J.A. Rosebrock, J.A. Britz, and T.R. Kramer. 2000. Measurement of T-lymphocyte responses in whole blood cultured using newly synthesized DNA and ATP. Clinical and Diagnostic Laboratory Immunology 7(2): 307-311

10 PHA Distribution of Normal and HIV+ Patients NormalHIV+ Homi Farzadegan. Johns Hopkins. 2000. IHV Meeting.

11 Measurement Of Cell Activation By Mitogens And Recall Antigens Therapy Changed B.J. Loechelt, M. Chan Children’s National Medical Center, Washington, D.C; 2000. Manuscript in Preparation.

12 Measurement Of Cell Activation By Mitogens And Recall Antigens B.J. Loechelt, M. Chan Children’s National Medical Center, Washington, D.C; 2000. Manuscript in preparation

13 COMPARISON OF RESPONDERS AND NON RESPONDERS TO P24 ANTIGEN IN HIV INFECTION COMPARED TO CONTROLS HIV- Controls HIV+ Non Responders HIV+ Responders p<0.01 Cunningham-Rundles, S. and J. Cervia. Cornell University School of Medicine. 2000. Manuscript in preparation. ATPATP

14 Wahren, B. et al. Karolinska Institute. 2000. IHV Meeting

15 Lymphocyte Stimulation 6 - 24 hours Influx of ions Surface receptor clustering RNA synthesis Cytokine production & release DNA replication 3 – 7 days Clonal Expansion Proliferation ATP 1/2 - 6 hours Lymphocyte Response Cylex In Vitro CMI Cytokine Assays Lympho- proliferation

16 Analytical Parameters Accuracy Precision Sensitivity Specificity Reproducibility Stability Standardization

17 AIDS Patient Management

18 Acknowledgements Susanna Cunnigham-Rundles: Cornell Brett Loechelt: George Washington Homi Farzadegan: Johns Hopkins Britta Wahren: Karolinska Tim Kramer: USDA Peter Sottong: Cylex Richard Kowalski: Cylex Julie Woodcock: Cylex


Download ppt "CDER Meeting: Surrogate Markers of Immunity Presenter: Judith A. Britz, Ph.D. October 16, 2000."

Similar presentations


Ads by Google